nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Haemolytic anaemia—Pemetrexed—lung cancer	0.032	0.032	CcSEcCtD
Metaxalone—Haemolytic anaemia—Teniposide—lung cancer	0.0259	0.0259	CcSEcCtD
Metaxalone—Haemolytic anaemia—Erlotinib—lung cancer	0.019	0.019	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Topotecan—lung cancer	0.0179	0.0179	CcSEcCtD
Metaxalone—Leukopenia—Crizotinib—lung cancer	0.0171	0.0171	CcSEcCtD
Metaxalone—Leukopenia—Pemetrexed—lung cancer	0.0156	0.0156	CcSEcCtD
Metaxalone—Anaphylactic shock—Pemetrexed—lung cancer	0.0142	0.0142	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Irinotecan—lung cancer	0.0127	0.0127	CcSEcCtD
Metaxalone—Leukopenia—Teniposide—lung cancer	0.0126	0.0126	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Gemcitabine—lung cancer	0.0123	0.0123	CcSEcCtD
Metaxalone—Haemolytic anaemia—Cisplatin—lung cancer	0.0123	0.0123	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Cisplatin—lung cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Irritability—Cisplatin—lung cancer	0.0106	0.0106	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Etoposide—lung cancer	0.0105	0.0105	CcSEcCtD
Metaxalone—Hypersensitivity—Pemetrexed—lung cancer	0.0105	0.0105	CcSEcCtD
Metaxalone—Hypersensitivity—Gefitinib—lung cancer	0.0104	0.0104	CcSEcCtD
Metaxalone—Dizziness—Crizotinib—lung cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Pruritus—Pemetrexed—lung cancer	0.0101	0.0101	CcSEcCtD
Metaxalone—Pruritus—Gefitinib—lung cancer	0.00999	0.00999	CcSEcCtD
Metaxalone—Vomiting—Crizotinib—lung cancer	0.00989	0.00989	CcSEcCtD
Metaxalone—Rash—Crizotinib—lung cancer	0.0098	0.0098	CcSEcCtD
Metaxalone—Dermatitis—Crizotinib—lung cancer	0.0098	0.0098	CcSEcCtD
Metaxalone—Leukopenia—Vinblastine—lung cancer	0.00963	0.00963	CcSEcCtD
Metaxalone—Dizziness—Pemetrexed—lung cancer	0.0094	0.0094	CcSEcCtD
Metaxalone—Leukopenia—Topotecan—lung cancer	0.00936	0.00936	CcSEcCtD
Metaxalone—Nausea—Crizotinib—lung cancer	0.00924	0.00924	CcSEcCtD
Metaxalone—Abdominal discomfort—Cisplatin—lung cancer	0.00921	0.00921	CcSEcCtD
Metaxalone—Jaundice—Irinotecan—lung cancer	0.0092	0.0092	CcSEcCtD
Metaxalone—Vomiting—Pemetrexed—lung cancer	0.00904	0.00904	CcSEcCtD
Metaxalone—Vomiting—Gefitinib—lung cancer	0.00898	0.00898	CcSEcCtD
Metaxalone—Rash—Pemetrexed—lung cancer	0.00896	0.00896	CcSEcCtD
Metaxalone—Dermatitis—Pemetrexed—lung cancer	0.00895	0.00895	CcSEcCtD
Metaxalone—Rash—Gefitinib—lung cancer	0.0089	0.0089	CcSEcCtD
Metaxalone—Dermatitis—Gefitinib—lung cancer	0.00889	0.00889	CcSEcCtD
Metaxalone—Anaphylactic shock—Topotecan—lung cancer	0.00853	0.00853	CcSEcCtD
Metaxalone—Hypersensitivity—Teniposide—lung cancer	0.00848	0.00848	CcSEcCtD
Metaxalone—Nausea—Pemetrexed—lung cancer	0.00844	0.00844	CcSEcCtD
Metaxalone—Nausea—Gefitinib—lung cancer	0.00839	0.00839	CcSEcCtD
Metaxalone—Pruritus—Teniposide—lung cancer	0.00814	0.00814	CcSEcCtD
Metaxalone—Leukopenia—Vinorelbine—lung cancer	0.008	0.008	CcSEcCtD
Metaxalone—Jaundice—Etoposide—lung cancer	0.00765	0.00765	CcSEcCtD
Metaxalone—Vomiting—Teniposide—lung cancer	0.00732	0.00732	CcSEcCtD
Metaxalone—Anaphylactic shock—Vinorelbine—lung cancer	0.0073	0.0073	CcSEcCtD
Metaxalone—Rash—Teniposide—lung cancer	0.00726	0.00726	CcSEcCtD
Metaxalone—Dermatitis—Teniposide—lung cancer	0.00725	0.00725	CcSEcCtD
Metaxalone—Headache—Teniposide—lung cancer	0.00721	0.00721	CcSEcCtD
Metaxalone—Nausea—Teniposide—lung cancer	0.00684	0.00684	CcSEcCtD
Metaxalone—Leukopenia—Irinotecan—lung cancer	0.0066	0.0066	CcSEcCtD
Metaxalone—Hypersensitivity—Vinblastine—lung cancer	0.00647	0.00647	CcSEcCtD
Metaxalone—Leukopenia—Gemcitabine—lung cancer	0.00643	0.00643	CcSEcCtD
Metaxalone—Jaundice—Docetaxel—lung cancer	0.00636	0.00636	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Methotrexate—lung cancer	0.0063	0.0063	CcSEcCtD
Metaxalone—Hypersensitivity—Topotecan—lung cancer	0.00629	0.00629	CcSEcCtD
Metaxalone—Pruritus—Topotecan—lung cancer	0.00604	0.00604	CcSEcCtD
Metaxalone—Anaphylactic shock—Irinotecan—lung cancer	0.00602	0.00602	CcSEcCtD
Metaxalone—Leukopenia—Cisplatin—lung cancer	0.00599	0.00599	CcSEcCtD
Metaxalone—Pruritus—Erlotinib—lung cancer	0.00597	0.00597	CcSEcCtD
Metaxalone—Tension—Paclitaxel—lung cancer	0.0059	0.0059	CcSEcCtD
Metaxalone—Anaphylactic shock—Gemcitabine—lung cancer	0.00586	0.00586	CcSEcCtD
Metaxalone—Nervousness—Paclitaxel—lung cancer	0.00584	0.00584	CcSEcCtD
Metaxalone—Irritability—Methotrexate—lung cancer	0.00582	0.00582	CcSEcCtD
Metaxalone—Dizziness—Vinblastine—lung cancer	0.00581	0.00581	CcSEcCtD
Metaxalone—Dizziness—Topotecan—lung cancer	0.00564	0.00564	CcSEcCtD
Metaxalone—Vomiting—Vinblastine—lung cancer	0.00558	0.00558	CcSEcCtD
Metaxalone—Dizziness—Erlotinib—lung cancer	0.00558	0.00558	CcSEcCtD
Metaxalone—Headache—Vinblastine—lung cancer	0.0055	0.0055	CcSEcCtD
Metaxalone—Leukopenia—Etoposide—lung cancer	0.00549	0.00549	CcSEcCtD
Metaxalone—Anaphylactic shock—Cisplatin—lung cancer	0.00546	0.00546	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—lung cancer	0.00546	0.00546	CcSEcCtD
Metaxalone—Vomiting—Topotecan—lung cancer	0.00542	0.00542	CcSEcCtD
Metaxalone—Leukopenia—Paclitaxel—lung cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Rash—Topotecan—lung cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Hypersensitivity—Vinorelbine—lung cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Dermatitis—Topotecan—lung cancer	0.00537	0.00537	CcSEcCtD
Metaxalone—Vomiting—Erlotinib—lung cancer	0.00537	0.00537	CcSEcCtD
Metaxalone—Somnolence—Irinotecan—lung cancer	0.00535	0.00535	CcSEcCtD
Metaxalone—Headache—Topotecan—lung cancer	0.00534	0.00534	CcSEcCtD
Metaxalone—Rash—Erlotinib—lung cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Dermatitis—Erlotinib—lung cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Headache—Erlotinib—lung cancer	0.00529	0.00529	CcSEcCtD
Metaxalone—Nausea—Vinblastine—lung cancer	0.00522	0.00522	CcSEcCtD
Metaxalone—Somnolence—Gemcitabine—lung cancer	0.00521	0.00521	CcSEcCtD
Metaxalone—Pruritus—Vinorelbine—lung cancer	0.00516	0.00516	CcSEcCtD
Metaxalone—Nausea—Topotecan—lung cancer	0.00507	0.00507	CcSEcCtD
Metaxalone—Abdominal discomfort—Methotrexate—lung cancer	0.00506	0.00506	CcSEcCtD
Metaxalone—Nausea—Erlotinib—lung cancer	0.00501	0.00501	CcSEcCtD
Metaxalone—Anaphylactic shock—Etoposide—lung cancer	0.00501	0.00501	CcSEcCtD
Metaxalone—Anaphylactic shock—Paclitaxel—lung cancer	0.00491	0.00491	CcSEcCtD
Metaxalone—Dizziness—Vinorelbine—lung cancer	0.00483	0.00483	CcSEcCtD
Metaxalone—Drowsiness—Methotrexate—lung cancer	0.0047	0.0047	CcSEcCtD
Metaxalone—Vomiting—Vinorelbine—lung cancer	0.00464	0.00464	CcSEcCtD
Metaxalone—Rash—Vinorelbine—lung cancer	0.0046	0.0046	CcSEcCtD
Metaxalone—Dermatitis—Vinorelbine—lung cancer	0.0046	0.0046	CcSEcCtD
Metaxalone—Headache—Vinorelbine—lung cancer	0.00457	0.00457	CcSEcCtD
Metaxalone—Leukopenia—Docetaxel—lung cancer	0.00456	0.00456	CcSEcCtD
Metaxalone—Somnolence—Etoposide—lung cancer	0.00445	0.00445	CcSEcCtD
Metaxalone—Hypersensitivity—Irinotecan—lung cancer	0.00443	0.00443	CcSEcCtD
Metaxalone—Somnolence—Paclitaxel—lung cancer	0.00436	0.00436	CcSEcCtD
Metaxalone—Nausea—Vinorelbine—lung cancer	0.00433	0.00433	CcSEcCtD
Metaxalone—Anaphylactic shock—Docetaxel—lung cancer	0.00416	0.00416	CcSEcCtD
Metaxalone—Pruritus—Gemcitabine—lung cancer	0.00415	0.00415	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—lung cancer	0.00407	0.00407	CcSEcCtD
Metaxalone—Hypersensitivity—Cisplatin—lung cancer	0.00403	0.00403	CcSEcCtD
Metaxalone—Dizziness—Irinotecan—lung cancer	0.00398	0.00398	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—lung cancer	0.00397	0.00397	CcSEcCtD
Metaxalone—Vomiting—Irinotecan—lung cancer	0.00383	0.00383	CcSEcCtD
Metaxalone—Rash—Irinotecan—lung cancer	0.0038	0.0038	CcSEcCtD
Metaxalone—Dermatitis—Irinotecan—lung cancer	0.00379	0.00379	CcSEcCtD
Metaxalone—Headache—Irinotecan—lung cancer	0.00377	0.00377	CcSEcCtD
Metaxalone—Vomiting—Gemcitabine—lung cancer	0.00373	0.00373	CcSEcCtD
Metaxalone—Somnolence—Docetaxel—lung cancer	0.0037	0.0037	CcSEcCtD
Metaxalone—Rash—Gemcitabine—lung cancer	0.0037	0.0037	CcSEcCtD
Metaxalone—Dermatitis—Gemcitabine—lung cancer	0.00369	0.00369	CcSEcCtD
Metaxalone—Hypersensitivity—Etoposide—lung cancer	0.00369	0.00369	CcSEcCtD
Metaxalone—Headache—Gemcitabine—lung cancer	0.00367	0.00367	CcSEcCtD
Metaxalone—Hypersensitivity—Paclitaxel—lung cancer	0.00362	0.00362	CcSEcCtD
Metaxalone—Nausea—Irinotecan—lung cancer	0.00358	0.00358	CcSEcCtD
Metaxalone—Pruritus—Etoposide—lung cancer	0.00354	0.00354	CcSEcCtD
Metaxalone—Nausea—Gemcitabine—lung cancer	0.00348	0.00348	CcSEcCtD
Metaxalone—Vomiting—Cisplatin—lung cancer	0.00347	0.00347	CcSEcCtD
Metaxalone—Pruritus—Paclitaxel—lung cancer	0.00347	0.00347	CcSEcCtD
Metaxalone—Rash—Cisplatin—lung cancer	0.00345	0.00345	CcSEcCtD
Metaxalone—Dermatitis—Cisplatin—lung cancer	0.00344	0.00344	CcSEcCtD
Metaxalone—Dizziness—Etoposide—lung cancer	0.00331	0.00331	CcSEcCtD
Metaxalone—Leukopenia—Methotrexate—lung cancer	0.00329	0.00329	CcSEcCtD
Metaxalone—Dizziness—Paclitaxel—lung cancer	0.00325	0.00325	CcSEcCtD
Metaxalone—Nausea—Cisplatin—lung cancer	0.00325	0.00325	CcSEcCtD
Metaxalone—Vomiting—Etoposide—lung cancer	0.00318	0.00318	CcSEcCtD
Metaxalone—Rash—Etoposide—lung cancer	0.00316	0.00316	CcSEcCtD
Metaxalone—Dermatitis—Etoposide—lung cancer	0.00315	0.00315	CcSEcCtD
Metaxalone—Headache—Etoposide—lung cancer	0.00314	0.00314	CcSEcCtD
Metaxalone—Tension—Doxorubicin—lung cancer	0.00312	0.00312	CcSEcCtD
Metaxalone—Vomiting—Paclitaxel—lung cancer	0.00312	0.00312	CcSEcCtD
Metaxalone—Rash—Paclitaxel—lung cancer	0.0031	0.0031	CcSEcCtD
Metaxalone—Dermatitis—Paclitaxel—lung cancer	0.00309	0.00309	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—lung cancer	0.00309	0.00309	CcSEcCtD
Metaxalone—Headache—Paclitaxel—lung cancer	0.00308	0.00308	CcSEcCtD
Metaxalone—Hypersensitivity—Docetaxel—lung cancer	0.00307	0.00307	CcSEcCtD
Metaxalone—Anaphylactic shock—Methotrexate—lung cancer	0.003	0.003	CcSEcCtD
Metaxalone—Nausea—Etoposide—lung cancer	0.00297	0.00297	CcSEcCtD
Metaxalone—Pruritus—Docetaxel—lung cancer	0.00294	0.00294	CcSEcCtD
Metaxalone—Nausea—Paclitaxel—lung cancer	0.00292	0.00292	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—lung cancer	0.00285	0.00285	CcSEcCtD
Metaxalone—Dizziness—Docetaxel—lung cancer	0.00275	0.00275	CcSEcCtD
Metaxalone—Somnolence—Methotrexate—lung cancer	0.00267	0.00267	CcSEcCtD
Metaxalone—Vomiting—Docetaxel—lung cancer	0.00265	0.00265	CcSEcCtD
Metaxalone—Rash—Docetaxel—lung cancer	0.00262	0.00262	CcSEcCtD
Metaxalone—Dermatitis—Docetaxel—lung cancer	0.00262	0.00262	CcSEcCtD
Metaxalone—Headache—Docetaxel—lung cancer	0.00261	0.00261	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—lung cancer	0.0026	0.0026	CcSEcCtD
Metaxalone—Nausea—Docetaxel—lung cancer	0.00247	0.00247	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—lung cancer	0.00231	0.00231	CcSEcCtD
Metaxalone—Hypersensitivity—Methotrexate—lung cancer	0.00221	0.00221	CcSEcCtD
Metaxalone—Pruritus—Methotrexate—lung cancer	0.00212	0.00212	CcSEcCtD
Metaxalone—Dizziness—Methotrexate—lung cancer	0.00198	0.00198	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—lung cancer	0.00191	0.00191	CcSEcCtD
Metaxalone—Vomiting—Methotrexate—lung cancer	0.00191	0.00191	CcSEcCtD
Metaxalone—Rash—Methotrexate—lung cancer	0.00189	0.00189	CcSEcCtD
Metaxalone—Dermatitis—Methotrexate—lung cancer	0.00189	0.00189	CcSEcCtD
Metaxalone—Headache—Methotrexate—lung cancer	0.00188	0.00188	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—lung cancer	0.00184	0.00184	CcSEcCtD
Metaxalone—Nausea—Methotrexate—lung cancer	0.00178	0.00178	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—lung cancer	0.00172	0.00172	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—lung cancer	0.00165	0.00165	CcSEcCtD
Metaxalone—Rash—Doxorubicin—lung cancer	0.00164	0.00164	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—lung cancer	0.00164	0.00164	CcSEcCtD
Metaxalone—Headache—Doxorubicin—lung cancer	0.00163	0.00163	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—lung cancer	0.00154	0.00154	CcSEcCtD
